Table 2.

Potential epigenetic treatments for neurodegenerative diseases.

Disease	Proteinopathy	Treatment	Mechanism of action	Ref.
AD	ApoE (sporadic)	MS275	Class I HDACi’s increased expression of apoE and astrocytic protein secretion.	Dresselhaus et al. (2018)
		Cl994
	Amyloid-Beta	BG45	Class I HDACi decreases phosphorylated tau and alleviates neuronal loss.	Han et al. (2022)
		Sulforaphane	HDACi restores histone acetylation.	Kim et al. (2017)
		BIX01294	HMT inhibitor ameliorates memory loss stores perturbed H3K9me2.	Zheng et al. (2019)
		Trichostatin A	Alleviates APP inhibitory effect induces transcription of Egr1.	Hendrickx et al. (2013)
		Sodium butyrate	HDACi decreases tau phosphorylation and restores histone acetylation.	Cao et al. (2018)
	Tau	WDR5-0103	HMT inhibitor restores perturbed H3K4me3, synaptic formations and memory.	Cao et al. (2020)
PD	Sporadic	Jard1A	HDM inhibitor reduces 𝛼-Syn levels Restores perturbed H3K4me3	Guhathakurta et al. (2021)
	Alpha synuclein	UNC0638	HMT inhibitor restores perturbed H3K9me1/me2 and expression of H3K9me3 target genes.	Sugeno et al. (2016)
		GSK-J4	KDM inhibitor restores perturbed H3K27me3.	Mu et al. (2020)
		Sodium butyrate	HDACi reduces 𝛼-Syn toxicity.	Kontopoulos et al. (2006)
FTD/ALS	SOD1	Trichostatin A	HDACi improves motor neuron survival and muscular atrophy.	Yoo and Ko (2011)
		Spermidine	Antioxidant targets lysine specific demethylase 1 and improves cellular survival.	Choi et al. (2022)
	TDP-43	4 phenylbutyrate	HDACi increases cellular survival and ameliorates TDP-43 toxicity.	Sanna et al. (2020)
		Trichostatin A
		Sodium butyrate
	FUS	Trichostatin A	HDACi restores perturbed histone acetylation and ameliorates FUS toxicity.	Bennett et al. (2021)
		ACY-738	HDACi increases life span, survival rate and restores motor neuron phenotypes.	Rossaert et al. (2019)
	C9orf72	JQ1	BRD4 inhibitor reduces cytotoxicity of Poly-PR	Chen et al. (2024)